Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if vitamin K supplementation three times per week reduces the progression of coronary artery calcification over 12 months in dialysis patients compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Rachel Holden
• Collaborator: Kingston General Hospital
• Treatments: Vitamin K; Vitamin K 1; Vitamins

Criteria

Inclusion Criteria:

• Able to provide signed informed consent

• ≥18 years of age

• Expected to survive one year

• Have end-stage kidney disease and require hemodialysis

• Have a baseline coronary artery calcification score ≥30 Agatston units (AUs)

Exclusion Criteria:

• Have a medical condition that requires warfarin

• Require hemodialysis for acute kidney injury

• Are Pregnant

• Have other severe co-morbid conditions (e.g. malignancy, disabling stroke) with life expectancy less than one year

• Have undergone coronary artery bypass grafting or have stents placed in their coronary arteries

• Are currently enrolled in another interventional trial